MedNet

Program Description

Inflammatory bowel diseases (IBD), commonly categorized as Crohn’s disease (CD) and ulcerative colitis (UC), are immune mediated chronic inflammatory disorders of the gastrointestinal tract. The etiopathogenesis is multifactorial, with different environmental, genetic, immune mediated, and gut microbial factors playing an important role. The current therapy goals are to improve clinical symptoms, control inflammation, prevent complications, and improve quality of life. The field of IBD therapeutics has seen tremendous improvements, and the efficacy of new drug targets such as IL-12/IL-23, the JAK/STAT pathway, and S1P has been established. Extra-intestinal manifestations (EIMs) are a common complication of IBD, affecting up to half of the patients. Despite their high prevalence, information on standardized definitions, diagnostic strategies, and treatment targets is limited.

Intended Audience

Gastroenterologists, internal medicine specialists, primary care physicians, nurse practitioners, physician assistants, and nurses caring for patients with IBDs.

Commercial Supporters

This activity is supported by an educational grant from Pfizer Inc. and Bristol Myers Squibb.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

Incorporate biologics, small molecule inhibitors, and biosimilars in the treatment of inflammatory bowel diseases (IBD)
Assess the interdisciplinary management strategies of extra-intestinal manifestations in people living with IBD

Accredited Providers

This activity is provided by Amedco, a CME/CE company, and MedNet.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Designation Statement

Amedco LLC designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) Credit Designation

Designation Statement

Amedco LLC designates this activity for a maximum of 1.25 ANCC contact hours.

Additional Credit Information

Note to Physician Assistants
PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credits^TM from organizations accredited by ACCME or a recognized state medical society

Note to Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allows reciprocity for AANPCP continuing education credit for a maximum of 1.25 hours.

Conflicts of Interest Policy

It is the policy of Amedco and MedNet to ensure activity content is balanced, independent, objective, and based on scientific best evidence. All persons in a position to control content (i.e., course director, planning committee member, and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to his/her presentation content.

Every person in a position to control content reported he/she does not have any relevant financial relationships with the industry (relative to the content of his/her presentation) to disclose.

Planners’ and Managers’ Disclosures

Miguel Regueiro, MD, discloses the following:
Unrestricted Educational Grants: Abbvie, Janssen, UCB, Pfizer, Takeda, Celgene, Genentech, Gilead, BMS, Lilly
Advisory Boards and Consultant: Abbvie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions, ALFASIGMA, S.p.A., BMS
CME Companies: CME Outfitters, lmedex, Gl Health Foundation (GiHF), Cornerstones, Remedy, MJH life sciences, Medscape, MDEducation, WebMD, HMPGiobal
Royalties and Editorships: Wolters Kluwer Health as Author/Editor of UpToDate, Crohn’s and Colitis Foundation as Editor-in-Chief, CC360

Kamatham A. Naidu, PhD, (MedNet) has no relevant financial relationships.
Brian Waggoner (MedNet) has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

It is the policy of Amedco and Medical Media Holdings to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she would notify the audience if/when the discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Faculty

Miguel Regueiro, MD
Professor
Department of Medicine,
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH

Dr. Regueiro discloses that he received unrestricted educational grants from Abbvie, Janssen, UCB, Pfizer, Takeda, Celgene, Genentech, Gilead, BMS, Lilly; on the advisory boards and consultant of Abbvie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions, ALFASIGMA, S.p.A., BMS; participated in CME companies: CME Outfitters, lmedex, Gl Health Foundation (GiHF), Cornerstones, Remedy, MJH life sciences, Medscape, MDEducation, WebMD, HMPGiobal; and holds royalties and editorships: Wolters Kluwer Health as Author/Editor of UpToDate, Crohn’s and Colitis Foundation as Editor-in-Chief, CC360Pfizer, X4 Pharma, Infinity, AstraZeneca, Bayer, Merck, ABX, Curium, Astellas, Dendreon.

Francis Farraye, MD, MSc
Director
Inflammatory Bowel Disease Center
Division of Gastroenterology and Hepatology
Mayo Clinic
Jacksonville, FL

Dr. Farraye discloses that he was on the advisory boards of Braintree, BMS, GI Reviewers, GSK, Iterative Health, Janssen, Pfizer, Sebela; holds stock in Innovation pharmaceuticals; and DSMB with Adiso Therapeutics, and Lilly.

Instructions

In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

For information about the accreditation of this program, please contact Sheryl Morgan (651-789-3730; email: Sheryl@AmedcoEmail.com

Privacy Policy

Amedco observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities that are relevant to their interests and/or the activities they support.

myCME privacy policy